XNAS · JUNS
-14.03% · -$0.8700 · Vol Not reported
Pre-market · updated 05:08:44 ET
Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$5.33
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
JUNS
Jupiter Neurosciences, Inc. Common Stock
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

24/ 100
Veridion Score
AVOID · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is JUNS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading JUNS catalysts
About Jupiter Neurosciences, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
5
Country
US

Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.20
Last session
Day high
$6.20
Last session
Day low
$6.20
Last session
Previous close
$6.20
52W high
$135.00
-96.05% from high
52W low
$4.61
1% of range
Market cap
$4.8M
EPS
$-4.2800
Beta
0.80
Shares out
770.1K
Avg volume
2M
VWAP
$6.20
Last session
Price history computed in-house
1W
+2.90%
1M
-41.27%
3M
-69.10%
1Y
-95.32%
YTD
-93.03%
SMA 50 $11.73 · below
SMA 200 $41.14 · below
52W position 1%

JUNS overview

Loading financial statements
Loading JUNS Form 4 filings
Public disclosures

Congress activity in JUNS

No receipt-qualified Congressional disclosure is present for JUNS in the cached public ledger.

Federal contracts

JUNS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for JUNS in this window.
Lobbying spend

JUNS lobbying filings, year to date.

Registered lobbying filings matched to Jupiter Neurosciences, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for JUNS in this window.
Loading news for JUNS
Analyst ratings
Sovereign unlock shows live analyst consensus for JUNS.
Options
Sovereign unlock shows live options positioning for JUNS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.